2018
Endogenous bradykinin and B1-B5 during angiotensin-converting enzyme inhibitor–associated angioedema
Hubers S, Kohm K, Wei S, Yu C, Nian H, Grabert R, Sexton DJ, Brown NJ. Endogenous bradykinin and B1-B5 during angiotensin-converting enzyme inhibitor–associated angioedema. Journal Of Allergy And Clinical Immunology 2018, 142: 1636-1639.e5. PMID: 30036596, PMCID: PMC6226317, DOI: 10.1016/j.jaci.2018.06.037.Peer-Reviewed Original Research
2016
Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema
Straka BT, Ramirez CE, Byrd JB, Stone E, Woodard-Grice A, Nian H, Yu C, Banerji A, Brown NJ. Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema. Journal Of Allergy And Clinical Immunology 2016, 140: 242-248.e2. PMID: 27913306, PMCID: PMC5705179, DOI: 10.1016/j.jaci.2016.09.051.Peer-Reviewed Original ResearchConceptsACE inhibitor-associated angioedemaResolution of symptomsVisual analog scaleAnalog scaleReceptor antagonistTreatment groupsBradykinin BEnzyme (ACE) inhibitor-associated angioedemaStudy drug administrationReceptor antagonist icatibantHours of presentationTreatment of attacksC1 inhibitor deficiencyBradykinin receptor antagonismFrequency of administrationVanderbilt University Medical CenterUniversity Medical CenterMassachusetts General HospitalTwo-thirdsAntagonist icatibantBowel edemaWhite patientsH2 blockersClinical efficacyInhibitor deficiency
2013
Pollen Count and Presentation of Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema
Straka B, Nian H, Sloan C, Byrd JB, Woodard-Grice A, Yu C, Stone E, Steven G, Hartert T, Teo KK, Pare G, McCarty CA, Brown NJ. Pollen Count and Presentation of Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema. The Journal Of Allergy And Clinical Immunology In Practice 2013, 1: 468-473.e4. PMID: 24565618, PMCID: PMC4042396, DOI: 10.1016/j.jaip.2013.05.003.Peer-Reviewed Original ResearchConceptsACE inhibitor-associated angioedemaRate of angioedemaSeasonal allergiesRamipril Global Endpoint TrialAngiotensin converting enzyme (ACE) inhibitorsEnzyme (ACE) inhibitor-associated angioedemaIncidence of angiotensinMonths of presentationAdverse drug eventsDate of presentationVanderbilt University Medical CenterUniversity Medical CenterMarshfield Clinic Personalized Medicine Research ProjectOngoing TelmisartanEndpoint trialsACE inhibitorsPollen countsDrug eventsAssociated angioedemaObservational studyCohort analysisMedical CenterHospital settingAngioedemaPersonalized Medicine Research Project
2010
Association of angiotensin‐converting enzyme inhibitor‐associated angioedema with transplant and immunosuppressant use
Byrd JB, Woodard‐Grice A, Stone E, Lucisano A, Schaefer H, Yu C, Eyler AE, Salloum NE, Brown NJ. Association of angiotensin‐converting enzyme inhibitor‐associated angioedema with transplant and immunosuppressant use. Allergy 2010, 65: 1381-1387. PMID: 20557296, PMCID: PMC3305268, DOI: 10.1111/j.1398-9995.2010.02398.x.Peer-Reviewed Original ResearchConceptsACE inhibitor-associated angioedemaEnzyme (ACE) inhibitor-associated angioedemaTransplant patientsImmunosuppressant useDipeptidyl peptidase IV activityPeptidase IV activityTransplant statusDPPIV activityCardiac transplant patientsRenal transplant patientsChronic renal failureAssociation of angiotensinEffects of immunosuppressantsIncidence of angioedemaActivity of DPPIVCardiac transplantImmunosuppressant therapyRenal failureConsecutive patientsACE inhibitorsImmunosuppressant agentsAngioedema casesUnivariate analysisAngioedemaSeasonal allergies
2009
Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated Angioedema
Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated Angioedema. Hypertension 2009, 54: 516-523. PMID: 19581505, PMCID: PMC2758288, DOI: 10.1161/hypertensionaha.109.134197.Peer-Reviewed Original ResearchConceptsACE inhibitorsRisk of angioedemaVildagliptin useDPP-IV inhibitorsComparator-treated patientsEnzyme (ACE) inhibitor-associated angioedemaStudy drug exposureAngiotensin receptor blockersPhase III studyPossible drug-drug interactionsIncidence of angioedemaCase report formsDipeptidyl peptidase IV inhibitorsDrug-drug interactionsDPP-IV inhibitor vildagliptinPathogenesis of angiotensinPeptidase IV inhibitorsAngioedema riskClinical angioedemaReceptor blockersIII studyAbsolute riskAdjudication committeeDPP-IV inhibitionDrug exposure
2007
Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema
Byrd JB, Touzin K, Sile S, Gainer JV, Yu C, Nadeau J, Adam A, Brown NJ. Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema. Hypertension 2007, 51: 141-147. PMID: 18025295, PMCID: PMC2749928, DOI: 10.1161/hypertensionaha.107.096552.Peer-Reviewed Original ResearchConceptsEnzyme (ACE) inhibitor-associated angioedemaDipeptidyl peptidase IV activityHistory of angiotensinPeptidase IV activityControl subjectsSubstance PDipeptidyl peptidase IVEnzyme inhibitorsLife-threatening adverse effectsAngiotensin converting enzyme (ACE) inhibitorsEnzyme inhibitionAbsence of angiotensinPrevalence of smokingSera of patientsCase-control studyPeptidase IVSubstrates of angiotensinTissue edemaAssociated angioedemaAminopeptidase P activityVascular permeabilityAngioedemaAngiotensinAminopeptidase N activityAmino-terminal degradation
1999
Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema
Blais C, Rouleau J, Brown N, Lepage Y, Spence D, Munoz C, Friborg J, Geadah D, Gervais N, Adam A. Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. Immunopharmacology 1999, 43: 293-302. PMID: 10596866, DOI: 10.1016/s0162-3109(99)00133-2.Peer-Reviewed Original ResearchConceptsDes-Arg9AE patientsC subjectsLife-threatening adverse reactionsEnzyme (ACE) inhibitor-associated angioedemaMetabolism of bradykininLocal inflammatory reactionEnzyme defectPreincubation of seraBK metabolismSensitive enzyme immunoassayB1 agonistSerum metabolismAdverse reactionsControl subjectsInflammatory reactionACEIAngioedemaAbnormal metabolismPatientsEnzyme inhibitorsSynthetic bradykininControl seraBradykininEnzyme immunoassay
1996
Black Americans have an increased rate of angiotensin converting enzyme inhibitor‐associated angioedema
Brown N, Ray W, Snowden M, Griffin M. Black Americans have an increased rate of angiotensin converting enzyme inhibitor‐associated angioedema. Clinical Pharmacology & Therapeutics 1996, 60: 8-13. PMID: 8689816, DOI: 10.1016/s0009-9236(96)90161-7.Peer-Reviewed Original ResearchConceptsACE inhibitor useEnzyme (ACE) inhibitor-associated angioedemaInhibitor useACE inhibitorsRelative riskWhite subjectsACE inhibitor-associated angioedemaACE inhibitor doseRate of angiotensinRetrospective cohort studyRisk of angioedemaTennessee Medicaid programAssociation of racePotential confounding factorsEffect of doseSpecific ACE inhibitorDiuretic useCohort studyConcurrent medicationsPatient characteristicsPrevious hospitalizationAngioedemaInhibitor doseConfounding factorsYears of useAngiotensin converting enzyme inhibitor‐associated angioedema: higher risk in blacks than whites
Burkhart G, Brown N, Griffin M, Ray W, Hammerstrom T, Weiss S. Angiotensin converting enzyme inhibitor‐associated angioedema: higher risk in blacks than whites. Pharmacoepidemiology And Drug Safety 1996, 5: 149-154. PMID: 15073831, DOI: 10.1002/(sici)1099-1557(199605)5:3<149::aid-pds222>3.0.co;2-i.Peer-Reviewed Original ResearchCalcium channel blockersIncidence of angioedemaWhite patientsHigh riskGreater incidenceGreater riskEnzyme (ACE) inhibitor-associated angioedemaRate of angioedemaRetrospective cohort studyRisk of angioedemaACEI exposureACEI useACEI usersAngioedema incidenceCCB usersCohort studyAngioedema casesFirst episodeACEIsChannel blockersAngioedemaMedicaid recipientsFull cohortEnzyme inhibitorsChronic exposure